• Leveljump Healthcare has acquired an additional percentage of Real Time Medical
  • The telehealth solutions company has acquired an additional 8.3-percent stake in Real Time Medical, a private Ontario company
  • The all-stock deal is worth approximately $924-thousand
  • The deal means Leveljump now owns a 25.21-percent interest in Real Time Medical
  • Leveljump Healthcare is unchanged, trading at $0.095 at 1:11 p.m. EST

Leveljump Healthcare (JUMP) has acquired an additional percentage of Real Time Medical.

The Toronto-based telehealth solutions company has acquired an additional 8.3-percent stake in Real Time Medical, a private Ontario company.

The all-stock deal is worth approximately $924-thousand.

The deal means Leveljump now owns a 25.21-percent interest in Real Time Medical.

The transaction has been approved by the TSX Venture Exchange.

In addition, Leveljump has agreed to purchase a promissory note, due from Real Time Medical to a vendor, with a face amount of $100,000 and accrued interest of approximately $30,000.

Leveljump continues to focus on profitable telehealth solutions as well as primary care services in radiology. T

The company’s subsidiary, CTS, provides off-site radiology readings for hospital emergency rooms and is a leader in the teleradiology space in Ontario.

Leveljump Healthcare is unchanged, trading at $0.095 at 1:11 p.m. EST.

More From The Market Online

Buzz on the Bullboards: Looking for volatility-proof stocks?

Investors saw developments in Canadian and U.S. stock markets, with attention on decisions made by central banks and moves in key sectors.
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.